This guideline is an addendum to the Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents - First version(CPMP/EWP/239/95). The guidance defines requirements for the clinical development of locally applied, locally acting products with known active substance. It provides guidance on the information to be included in the dossier.

Keywords: Therapeutic equivalence, gastrointestinal, locally applied and locally acting, pharmacokinetic, bioequivalence

Current effective version

Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1

AdoptedLegal effective date: Reference Number: CPMP/EWP/239/95 Rev. 1 Corr.Summary:

This guideline is an addendum to the ‘Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents' (CPMP/EWP/239/95).

English (EN) (455.51 KB - PDF)

First published: Last updated:
View

Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents - First version

AdoptedLegal effective date: Reference Number: CHMP/EWP/239/95 final

English (EN) (38.87 KB - PDF)

First published: Last updated:
View

Document history

Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract - Revision 1

AdoptedLegal effective date: Reference Number: CPMP/EWP/239/95 Rev. 1 Corr.Summary:

This guideline is an addendum to the ‘Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents' (CPMP/EWP/239/95).

English (EN) (455.51 KB - PDF)

First published: Last updated:
View

Overview of comments received on 'Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract' (EMA/CPMP/EWP/239/95 Rev.1) - Revision 1

Reference Number: EMA/CHMP/648051/2017

English (EN) (497.08 KB - PDF)

First published:
View

Draft guideline on equivalence studies for the demonstration of therapeutic equivalence for products that are locally applied, locally acting in the gastrointestinal tract as addendum to the guidance CHMP/EWP/239/95 - Revision 1

Consultation dates: to Draft: consultation closedReference Number: CPMP/EWP/239/95 Rev. 1Summary:

This guideline defines the requirements that need to be fulfilled to waive clinical trials with clinical or pharmacodynamic endpoints in the demonstration of therapeutic equivalence for locally applied, locally acting gastrointestinal products. It also defines the in vivo bioequivalence studies and in vitro equivalence tests that are necessary.

English (EN) (318.3 KB - PDF)

First published: Last updated:
View

Concept paper on the development of a guideline on the demonstration of therapeutic equivalence for locally applied and locally acting products in the gastrointestinal tract - Revision 1

Consultation dates: to Draft: consultation closedReference Number: EMA/CHMP/558326/2013Summary:

The note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents provides general recommendations on the clinical requirements for respective formulations with known active substances. This concept paper discusses the need to expand the guidance on locally applied and locally acting gastrointestinal products.

English (EN) (115.01 KB - PDF)

First published: Last updated:
View

How useful do you find this page?